Success Metrics

Clinical Success Rate
47.6%

Based on 10 completed trials

Completion Rate
48%(10/21)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
11(52%)

Phase Distribution

Ph phase_3
8
38%
Ph phase_2
5
24%
Ph phase_4
8
38%

Phase Distribution

0

Early Stage

5

Mid Stage

16

Late Stage

Phase Distribution21 total trials
Phase 2Efficacy & side effects
5(23.8%)
Phase 3Large-scale testing
8(38.1%)
Phase 4Post-market surveillance
8(38.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

47.6%

10 of 21 finished

Non-Completion Rate

52.4%

11 ended early

Currently Active

0

trials recruiting

Total Trials

21

all time

Status Distribution
Completed(10)
Terminated(11)

Detailed Status

Terminated11
Completed10

Development Timeline

Analytics

Development Status

Total Trials
21
Active
0
Success Rate
47.6%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (23.8%)
Phase 38 (38.1%)
Phase 48 (38.1%)

Trials by Status

terminated1152%
completed1048%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT04891302Phase 2

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

Completed
NCT04347915Phase 2

The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19

Completed
NCT00362505Phase 3

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Terminated
NCT00362700Phase 2

Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201

Terminated
NCT00313287Phase 3

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV

Terminated
NCT00313274Phase 3

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV

Terminated
NCT01264094Phase 4

A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period

Terminated
NCT00672867Phase 3

A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B

Completed
NCT01264367Phase 4

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

Completed
NCT01266005Phase 4

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

Terminated
NCT01192854Phase 3

An Study of Efficacy and Safety of Clevudine

Completed
NCT00313261Phase 2

Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

Terminated
NCT00362635Phase 3

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

Completed
NCT00558493Phase 4

Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients

Completed
NCT00558818Phase 4

Long-term Study With Clevudine

Completed
NCT00641082Phase 4

A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Completed
NCT00798460Phase 4

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Terminated
NCT00501124Phase 4

Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV

Completed
NCT00496002Phase 3

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

Terminated
NCT00496158Phase 3

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
21